AnaptysBio Inc (ANAB):企業の財務・戦略的SWOT分析

◆英語タイトル:AnaptysBio Inc (ANAB) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH134569FSA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

AnaptysBio Inc (ANAB) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody product candidates for the treatment of inflammatory, autoimmune and atopic diseases. The company develops its product candidates through its proprietary antibody discovery technology platform, that is based on somatic hypermutation (SHM). Its product candidates are being developed for the treatment of moderate-to-severe adult atopic dermatitis, asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis and for the treatment of human autoimmune diseases. The company has partnership with GlaxoSmithKline and Bristol-Myers Squibb, to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.

AnaptysBio Inc Key Recent Developments

Nov 04,2020: AnaptysBio announces third quarter 2020 financial results and provides pipeline updates
Aug 10,2020: AnaptysBio announces second quarter 2020 financial results and provides pipeline updates
Jul 31,2020: Anaptysbio appoints Dr. Paul F. Lizzul as chief medical officer
Jul 15,2020: AnaptysBio expands executive leadership team
May 06,2020: AnaptysBio announces first quarter 2020 financial results and provides pipeline updates

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
AnaptysBio Inc – Key Facts
AnaptysBio Inc – Key Employees
AnaptysBio Inc – Key Employee Biographies
AnaptysBio Inc – Major Products and Services
AnaptysBio Inc – History
AnaptysBio Inc – Company Statement
AnaptysBio Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
AnaptysBio Inc – Business Description
AnaptysBio Inc – Corporate Strategy
AnaptysBio Inc – SWOT Analysis
SWOT Analysis – Overview
AnaptysBio Inc – Strengths
AnaptysBio Inc – Weaknesses
AnaptysBio Inc – Opportunities
AnaptysBio Inc – Threats
AnaptysBio Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
AnaptysBio Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 04, 2020: AnaptysBio announces third quarter 2020 financial results and provides pipeline updates
Aug 10, 2020: AnaptysBio announces second quarter 2020 financial results and provides pipeline updates
Jul 31, 2020: Anaptysbio appoints Dr. Paul F. Lizzul as chief medical officer
Jul 15, 2020: AnaptysBio expands executive leadership team
May 06, 2020: AnaptysBio announces first quarter 2020 financial results and provides pipeline updates
Mar 02, 2020: AnaptysBio announces fourth quarter and full year 2019 financial results and provides pipeline updates
Nov 08, 2019: AnaptysBio announces third quarter 2019 financial results and provides pipeline updates
Aug 08, 2019: AnaptysBio announces second quarter 2019 financial results and provides pipeline updates
May 07, 2019: AnaptysBio announces first quarter 2019 financial results and provides pipeline updates
Feb 28, 2019: AnaptysBio announces fourth quarter and full year 2018 financial results and provides pipeline updates
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
AnaptysBio Inc, Key Facts
AnaptysBio Inc, Key Employees
AnaptysBio Inc, Key Employee Biographies
AnaptysBio Inc, Major Products and Services
AnaptysBio Inc, History
AnaptysBio Inc, Subsidiaries
AnaptysBio Inc, Key Competitors
AnaptysBio Inc, Ratios based on current share price
AnaptysBio Inc, Annual Ratios
AnaptysBio Inc, Annual Ratios (Cont...1)
AnaptysBio Inc, Interim Ratios
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
AnaptysBio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[AnaptysBio Inc (ANAB):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PT Kideco Jaya Agung:企業の戦略・SWOT・財務情報
    PT Kideco Jaya Agung - Strategy, SWOT and Corporate Finance Report Summary PT Kideco Jaya Agung - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Kirby Corp (KEX):企業の財務・戦略的SWOT分析
    Kirby Corp (KEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bank of Montreal:企業のM&A・事業提携・投資動向
    Bank of Montreal - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Montreal Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Rohto Pharmaceutical Co Ltd (4527):企業の財務・戦略的SWOT分析
    Summary Rohto Pharmaceutical Co Ltd (Rohto Pharmaceutical) is a pharmaceutical company that manufactures and markets cosmetics and functional foods. The company offers products such as eye care products, skin care products, oral medicine product, cosmetics, eye drops, gastrointestinal medicines, der …
  • Xintela AB (XINT):企業の財務・戦略的SWOT分析
    Summary Xintela AB (Xintela) is a biomedical company that develops treatment for cartilage damage and brain tumors. The company’s technology includes Xinmark, a patented marker technology developed to identify and select certain types of tumor cells, which can develop into cartilage cells. It also o …
  • Scandinavian Biopharma Holding AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Scandinavian Biopharma Holding AB (Scandinavian) is a biotechnology company that distributes vaccines and immunoglobulin. The company offers diagnostics, vaccines, dental and immunoglobulin products. Its products are used in the therapeutic areas of diphtheria and tetanus, tuberculosis, poli …
  • Boyd Gaming Corporation:企業のM&A・事業提携・投資動向
    Boyd Gaming Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Boyd Gaming Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Anheuser-Busch InBev NVSA (ABI):企業の財務・戦略的SWOT分析
    Anheuser-Busch InBev NVSA (ABI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Bank of Chongqing Co Ltd:企業の戦略・SWOT・財務分析
    Bank of Chongqing Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bank of Chongqing Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • IntriCon Corp (IIN)-医療機器分野:企業M&A・提携分析
    Summary IntriCon Corp (IntriCon) is a designer, developer and manufacturer of miniature and micro-miniature body-worn medical and electronics products. The company’s products include glucose monitoring, medical coils, cardiac monitoring, amplifiers, systems, plastic medical molding, support products …
  • Hanmi Pharmaceuticals Co Ltd (128940)-製薬・医療分野:企業M&A・提携分析
    Summary Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company’s prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counte …
  • Lidds AB (LIDDS):企業の財務・戦略的SWOT分析
    Summary Lidds AB (Lidds) is a developer of pharmaceutical products for the treatment of cancer and other diseases. The company offers Liproca Depot, an injectable product used for the treatment of prostate cancer. Its Liproca is a bioresorbable, biocompatible and locally injectable modified release …
  • Colonial Penn Life Insurance Company:企業の戦略・SWOT・財務情報
    Colonial Penn Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Colonial Penn Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Zoomlion Heavy Industry Science and Technology Co., Ltd.:戦略・SWOT・企業財務分析
    Zoomlion Heavy Industry Science and Technology Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Zoomlion Heavy Industry Science and Technology Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the comp …
  • Checkpoint Systems, Inc.:企業の戦略・SWOT・財務分析
    Checkpoint Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Checkpoint Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Expedia Inc:企業のM&A・事業提携・投資動向
    Expedia Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Expedia Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • ARUP Laboratories:企業の戦略的SWOT分析
    ARUP Laboratories - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Inhibrx LP:製薬・医療:M&Aディール及び事業提携情報
    Summary Inhibrx LP (Inhibrx) is a biotherapeutic company that develops drugs for treatment of oncology, infectious disease and inflammatory diseases. The company’s products include therapeutic proteins with multivalent and multi specific molecules which are designed from their antibody technology. I …
  • SK E&S Co Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary SK E&S Co Ltd (SK E&S) a subsidiary of SK Holdings Co Ltd is a utility service provider that offers natural gas and electricity distribution. The company’s business activities include city gas, district energy, power, overseas business and LNG. It operates and supplies electricity from its L …
  • Telephonics Corp:企業の戦略的SWOT分析
    Telephonics Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆